

Special Issue

Formulation and Delivery Technologies for mRNA Vaccines

Message from the Guest Editor

The recent Covid-19 pandemic prompted the development of mRNA vaccines with the advantage of fast production in large scales. Two mRNA vaccines (Pfizer BNT162b2 and Moderna mRNA-1273) were developed in an unprecedented speed that showed more than 90% protective efficacy. Lipid nanoparticles play a crucial role in protection of mRNA from degradation and facilitation of intracellular delivery. Although currently approved mRNA vaccines contain no adjuvants, formulation of mRNA vaccines with new or traditional adjuvants may further enhance its efficacy. Currently approved mRNA vaccines are mainly administered by needle injection. Needle-free delivery technologies may relieve the pain and increase its acceptance rate. Besides infectious diseases, mRNA vaccines also hold a great promise to induce potent anti-tumor immunity. This special issue will focus on formulation and delivery technologies for mRNA vaccines against infectious diseases and cancer. Research articles, reviews, communications are all welcome.

Guest Editor

Dr. Xinyuan Chen

Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA

Deadline for manuscript submissions

closed (20 October 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/122748

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).